Introduction: One in four women carry group B streptococci vaginally, which can infect the amniotic fluid before delivery or can infect the baby during delivery, causing sepsis, pneumonia, or meningitis. Very low-birthweight infants are at much higher risk of infection or mortality, with up to 3% infected and mortality rates of up to 30%, even with immediate antibiotic treatment. Late-onset group B streptococcal infection begins from 7 days of age, and usually causes fever or meningitis, but is less often fatal compared with early infection.
Methods And Outcomes: We conducted a systematic review and aimed to answer the following clinical question: what are the effects of prophylactic treatment of asymptomatic neonates less than 7 days old with known risk factors for early-onset group B streptococcal infection? We searched: Medline, Embase, The Cochrane Library, and other important databases up to November 2013 (Clinical Evidence reviews are updated periodically, please check our website for the most up-to-date version of this review). We included harms alerts from relevant organisations such as the US Food and Drug Administration (FDA) and the UK Medicines and Healthcare products Regulatory Agency (MHRA).
Results: We found 5 studies that met our inclusion criteria. We performed a GRADE evaluation of the quality of evidence for interventions.
Conclusions: In this systematic review we present information relating to the effectiveness and safety of the following interventions: different antibiotics, monitoring and selective treatment, and routine antibiotic prophylaxis.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3938141 | PMC |
Res Vet Sci
December 2024
Metabolic Modifiers for Aquaculture, Agricultural Biotechnology Department, Center for Genetic Engineering and Biotechnology (CIGB), 31st Avenue and 190, Havana 10600, Cuba. Electronic address:
J Pharm Pract
January 2025
Emergency Medicine, Department of Pharmacy, Long Island Jewish Valley Stream, Valley Stream, NY, USA.
Ceftriaxone is a third-generation cephalosporin commonly used for treating bacteremia caused by gram-positive organisms such as and gram-negative organisms such as Enterobacterales. The typical doses for treating bacteremia are either 1 gram or 2 grams daily. Despite its widespread use, there are limited data on the optimal treatment dose for bacteremia.
View Article and Find Full Text PDFVet Microbiol
January 2025
Department of Animal Science, ETSEA, Universitat de Lleida, Lleida 25198, Spain. Electronic address:
Streptococcus suis (S. suis) is a major pathogen for pigs, causing large economic losses to the swine industry. Moreover, this bacterium has a zoonotic potential, being capable of infecting humans in close contact with pigs or, less frequently, through contact with pork products.
View Article and Find Full Text PDFmBio
January 2025
Antimicrobial Resistance, Omics and Microbiota Group, Centre for Systems Health and Integrated Metabolic Research, Department of Biosciences, Nottingham Trent University, Nottingham, United Kingdom.
is an unusual diderm firmicute that plays a central role in the formation of dental biofilm formation through coaggregation with many other oral bacteria. However, the molecular interactions leading to oral biofilm formation are largely unknown. In a recent study (L.
View Article and Find Full Text PDFJ Contemp Dent Pract
September 2024
Graduate Program in Dentistry, Federal University of Pelotas, Pelotas, Rio Grande do Sul, Brazil; Department of Dentistry, Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, The Netherlands, ORCID: https://orcid.org/0000-0002-5166-8233.
Aim: This study aimed to assess if the addition of origanum oil to denture materials could decrease microorganisms counts and biofilm formation without changing their mechanical/surface properties.
Materials And Methods: A total of 66 resilient denture liner discs (SoftConfort, Dencril Comércio de Plásticos Ltda, SP, Brazil) were prepared with fixed dimensions of 10 × 3 mm for biofilm assay ( = 36) and 12 × 2 mm for sorption-solubility tests ( = 30) containing three oil concentrations - 0, 2.5 and 5%, thereby = 12 per each group samples for biofilm assay and = 10 per each group for sorption-solubility test respectively.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!